Vitamin c and iron combo takes on brain cancer in early trial

NCT ID NCT04900792

Ongoing Disease control Sponsor: Bryan Allen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times

Summary

This early-phase trial tests whether adding high-dose vitamin C and an iron supplement (ferumoxytol) to standard radiation and chemotherapy can help adults with newly diagnosed glioblastoma, an aggressive brain tumor. The study includes 17 participants and focuses on finding a safe dose. Researchers will also track how long patients live without the cancer growing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: vitamin C (ascorbate) and ferumoxytol (an iron supplement)
What this could lead to: If it works, this could point toward a way to boost standard treatment for glioblastoma, potentially helping patients live longer.
What could go wrong: This is a very early phase 1 trial with only 17 people, so it's mainly checking safety, not effectiveness. The added treatments may cause side effects or not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE MIDLINE GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse intrinsic pontine glioma glioblastoma glioma susceptibility 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA GLIOBLASTOMA MULTIFORME

Contacts and locations

Locations

Department of Radiation Oncology at University of Iowa

Iowa City, Iowa, 52242, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.